Reviews: 2018 Medicinal Chemistry Reviews

Ref. n°: REV2018

Volume : 53
Editor-In-Chief : Joanne J. Bronson

Medicinal Chemistry Reviews is an outstanding 680 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format. Members can also order a print copy, for the cost of printing, shipping and handling

Table of contents

Chapter 1Diversity and Me: My Life as a Woman in Chemistry
Ann E. Weber
Chapter 2A Journey in Cardiovascular Drug Discovery: New Frontiers and Lessons Learned
Ruth Wexler
Chapter 3Recent Advances in the Development of Phosphodiesterase 10A Tracers for Positron Emission Tomography Imaging
Essa Hu
Chapter 4Pharmacology and Therapeutic Potential of the 5-HT7 Receptor: Beyond the Central Nervous System
Kevin M. Blattner, Daniel J. Canney, Benjamin E. Blass and Douglas A. Pippin
Chapter 5Recent Progress in Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors for the Treatment of Parkinson's Disease
Douglas S. Williamson, Morten Jørgensen and Kenneth V. Christensen
Chapter 6Emerging Targets for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Peter T.W. Cheng, James R. Corte, Alicia Regueiro-Ren and Dong Cheng
Chapter 7Injectable Diabetes Treatments Targeting Glucose Regulation and Satiety Pathways
James C. Lanter, Yue-Mei Zhang and Mark J. Macielag
Chapter 8Discovery and Therapeutic Relevance of Small-Molecule NOX4 Inhibitors
E. Blake Watkins, Osman F. Güner, Amol Kulkarni, Bernard Lassègue, Kathy K. Griendling and J. Phillip Bowen
Chapter 9Recent Advances in the Discovery of Inhaled Anti-Inflammatory Treatments
Peter Sjö, Frank Narjes and Martin Hemmerling
Chapter 10Advances in the Discovery and Development of Selective Tyrosine Kinase 2 (TYK2) Inhibitors
David S. Weinstein and Ryan M. Moslin
Chapter 11Covalent Inhibitors as Anti-Inflammatory Agents
Sami Osman and Michael Friedman
Chapter 12The Evolution of Selective FGFR4 Inhibitors for FGF19-Driven Malignancies
Joseph L. Kim, Chandra Miduturu, Megan A. Hatlen, Klaus P. Hoeflich, and Timothy Guzi
Chapter 13Isoform-Selective Histone Deacetylase (HDAC) Inhibitors in the Treatment of Cancer
Charles A. Blum and Matthew B. Jarpe
Chapter 14Emerging Non-Canonical Small-Molecule Inhibitors of Androgen Receptor (AR) and AR Interactome Partners for the Treatment of Castrate-Resistant Prostate Cancer
David B. Freeman, André Richters, Marius S. Pop, Nicholas B. Struntz, and Angela N. Koehler
Chapter 15Recent Trends in Malaria Research
Christoph Boss and Sergio Wittlin
Chapter 16Advances in Antifungal Drug Development
James M. Balkovec
Chapter 17Recent Progress on Small-Molecule Influenze Virus Inhibitors
Michael P. Clark and Paul S. Charifson
Chapter 18Therapeutic Potential of Alpha V Integrin Antagonists in TGFβ-Driven Disease
James E. Dowling, Fu-Yang Lin, Blaise Lippa, and Dawn Troast
Chapter 19Therapeutic Applications of Nanobodies
Srinivasa Karra and Sean McKenna
Chapter 20HIV Integrase Inhibitors: Biochemical, QSAR, and Docking Studies
Omobolanle Janet Jesumoroti, Rosalyn Klein, and Paul Watts
Chapter 21Physical Chemical Properties for Drug Design in Beyond Rule-of-Five Chemical Space
Marina Shalaeva, Gilles Goetz, and Laurence Philippe
Chapter 22Drug Metabolism and Pharmacokinetics Perspectives for Covalent Inhibitor Drug Development
Richard Zang, Shuguang Ma, and Matthew Wright
Chapter 23Development of Small-Molecule Inhibitors of Monoacylglycerol Lipase for the Treatment of Neurologic Diseases
John J.M. Wiener, Justin S. Cisar, Daniel J. Buzard, Olivia D. Weber, and Cheryl A. Grice
Chapter 24Recent Advances in Small-Molecule TLR7 Agonists for Drug Discovery
Alex Cortez and Porino Va
Chapter 25Case History: Orkambi® (Ivacaftor/Lumacaftor), for the Treatment of Cystic Fibrosis Patients who are Homozygous for the F508del CFTR Mutation
Sabine Hadida, Fred Van Goor, Paul Negulescu, and Peter D.J. Grootenhuis
Chapter 26Case History: IDHIFA® (Enasidenib), a First-in-Class Selective IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
Zenon D. Konteatis and Zhihua Sui
Chapter 27Case History: Curing Genotype 1-6 Hepatitis C: Velpatasvir, the NS5A Inhibitor in Epclusa® and Vosevi®
John O. Link
Chapter 28New Chemical Entities Entering Phase III Trials in 2017
Adam J. Schrier, Nathan E. Wright, Gregory T. Notte, and Amy S. Lee
Chapter 29To Market, To Market--2017
Catherine A. Bolger, Joseph E. Carpenter, T.G. Murali Dhar, Achal Pashine, Peter S. Dragovich, James H. Cook, Eric P. Gillis, Kevin M. Peese, and J. Robert Merritt